abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Esta página no está disponible en Español y está siendo mostrada en English

Respuesta de la empresa

1 Nov 2006

Autor:
Novartis

Response by Novartis to statement by Physicians for Social Justice (Nigeria)

Dr. Igboekwu raises many points and we would like to comment on two specific assumptions he makes. The first is that generic competition makes medicines more affordable to patients in the developing world, and the second is that generics are the panacea to enabling access to medicines.

Línea del tiempo